29 August 2018
Visiongain’s new report Global Anti-Obesity Drugs Market Forecast 2017-2027: Incretin mimetics/GLP-1 agonists, SNDRIs, lipase inhibitors, serotonin receptor agonists, sympathomimetic-GABA receptor agonists, sympathomimetics and others indicates that the global anti-obesity drugs market will see $3,513m in spending in 2021.
The global anti-obesity drugs market is expected to grow at a CAGR of 27.1% in the first half of the forecast period and CAGR of 38.7% in the second half of the forecast period. The market is expected to grow at a CAGR of 32.8% from 2016 to 2027. The market is estimated at $1,058 million in 2016, $3,513 million in 2021, and $24,063 million in 2027.
The lead analyst of the report said: “Despite the presence of several challenges, the Global Anti-Obesity Drugs market is expected to pose a significant growth rate during the forecast period. This is mainly because of some emerging trends that could exert a positive impact on the market. One such trend is an increasing focus on emerging markets. Due to an increase in population and improved accessibility to disease monitoring and disease management, key companies have begun to focus on the emerging markets such as Brazil, Russia, India, and China.
The changing perception about the disease from the view of patient, payer and government will pose significant growth over the forecast period. Moreover, molecules with novel MoA are under development with expected safe and effective clinical profiles compared to marketed drugs. Though the market is not crowded with branded drugs, it has witnessed intense competitive rivalry to gain market share, when it comes to newly launched medications.”
The 205-page report contains 78 tables and 140 figures that add visual analysis in order to explain the developing trends within the Global Anti-Obesity Drugs Market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Incretin mimetics/GLP-1 agonists, SNDRIs, lipase inhibitors, serotonin receptor agonists, sympathomimetic-GABA receptor agonists, sympathomimetics.
The 205-page report offers market forecasts and analysis for 12 leading national markets and the rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the anti-obesity drugs market.
The report Global Anti-Obesity Drugs Market Forecast 2017-2027: Incretin mimetics/GLP-1 agonists, SNDRIs, lipase inhibitors, serotonin receptor agonists, sympathomimetic-GABA receptor agonists, sympathomimetics and othersreport will be of value to anyone who wants to better understand the anti-obesity drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the anti-obesity drugs industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.